Wall Street Associates’s Aratana Therapeutics, Inc. PETX Stock Holding History

Wall Street Associates’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.01M	Sell	140,300 -57,100	-29%	-$462K	0.67%	60
2016 Q3	$1.85M	Buy	+197,400	New	+$1.64M	0.63%	69
2014 Q3	–	Sell	-67,597	Closed	-$1.05M	–	349
2014 Q2	$1.05M	Sell	67,597 -7,700	-10%	-$109K	0.09%	209
2014 Q1	$1.4M	Buy	+75,297	New	+$1.51M	0.11%	195

Other funds holding PETX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wall Street Associates's PETX Position: Q4 2016 in Review

Wall Street Associates reduced its Aratana Therapeutics, Inc. (PETX) stake by 29% in Q4 2016, selling an estimated $462K and leaving 140,300 shares worth $1.01M. The position accounts for 0.67% of the portfolio, ranked #60.

Wall Street Associates first reported a position in PETX in Q1 2014 and has held it in 4 quarters since. The position peaked at $1.85M in Q3 2016. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

Wall Street Associates held 140,300 shares of Aratana Therapeutics, Inc. worth $1.01M as of Q4 2016.
Wall Street Associates sold 57,100 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $462K.
Aratana Therapeutics, Inc. made up 0.67% of Wall Street Associates's portfolio in Q4 2016, its #60 holding.
Wall Street Associates first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and has held it in 4 quarters since.
Wall Street Associates's Aratana Therapeutics, Inc. position peaked at $1.85M in Q3 2016.
107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.